access intranet after hours circle-arrow apply blog caret circle arrow close closer look community outreach community outreach contact contact us down arrow facebook lock solid find a provider find a clinical trial find a provider find a researcher find faculty find-a-service how to apply join leadership left arrow locations logo make a gift map location maximize minimize my chart my chart notification hp notification lp next chevron right nxt prev pay your bill play previous quality and safety refer a patient request a speaker request appointment request an appointment residents corner rss search search jobs Asset 65 submit a story idea symptom checker Arrow Circle Up twitter youtube Dino Logo External Link University Logo Color University Logo Solid Health Logo Solid Arrow Right Circle Book Calendar Date Calendar Search Date Diploma Certificate Dollar Circle Donate Envelope Graduation Cap Map Pin Map Search Phone Pills Podcast

Cancer Instagram

Cancer Instagram
IMAGE: COURTESY OF DR. CARSTEN KRIEG

Snapshot of immune system proteins predicts patients’ response to immunotherapy

BY MATTHEW GRESETH

Checkpoint therapy blocking PD-1, a cellular surface marker that dampens the immune response, has revolutionized cancer care, enhancing overall survival in 33 to 40 percent of melanoma patients. However, it does not work in most patients and can have adverse effects and considerable costs to the health care system. Thus, it is crucial to identify patients likely to benefit from blocking PD-1 before administering therapy. MUSC Hollings Cancer Center researcher Carsten Krieg, Ph.D., an assistant professor in the MUSC Department of Microbiology and Immunology and the Department of Dermatology, and colleagues are using a novel technology to answer that question.

The technology, single-cell mass cytometry (called “Helios”), allows Krieg to generate an ‘Instagram’ of a patient’s immune system to identify the molecular details of the immune cells. An article reporting these results was featured on the cover of the February 2018 Nature Medicine (doi: 10.1038/nm.4466).

To date, researchers have tried to use patient-derived killer T-cells to identify biomarkers; however, this approach is limited by the small sample sizes that can be attained. Krieg and others in the field are starting to widen their approach by collecting peripheral blood mononuclear cells from a simple blood draw, so-called liquid biopsies. The cells are stained with metal-conjugated antibodies that target surface and intracellular proteins. This allows for sensitive detection of more than 30 proteins on a single cell over millions of blood cells. The stained cells are placed in Helios and are ionized. Because the metals placed on each antibody weigh differently, the resulting ions can be separated into different pools. Using artificial intelligence–guided bioinformatics and expert-guided analysis, researchers can create “immune instagrams,” or simplified visualizations of the blood immune response in a tumor patient.

Using this technology, Krieg and his colleagues confirmed that, as intended, T cells respond to anti-PD-1 immunotherapy. They showed that the frequency of classical monocytes, a type of immune cell, in the peripheral blood correlated with a patient’s response rate: the more monocytes in the blood, the better the response to anti-PD-1 therapy.

Generating immune profiles enables clinicians to sort patients towards immunotherapeutic regimens to which they are most likely to respond, thus supporting precision medicine. Not only will this technology allow clinicians to identify the subset of advanced melanoma patients who will respond positively to anti-PD-1 therapy, it may also identify alternative targets for patients who would not respond. Additionally, since this approach uses a simple blood test, samples could be taken throughout the treatment regimen. This would allow clinicians to monitor any changes to patients’ profiles that might require changes to their treatment.

“Here at MUSC, we hope to use the technology to help clinicians monitor success in their clinical trials or tell them to switch the immunotherapy,” says Krieg.

Watch an interview with Dr. Krieg on the oncology page of the MUSC Health Medical Video Center (MUSChealth.org/medical-video).